{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:11Z","timestamp":1793502911871,"version":"4.5.0"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Patients with chronic kidney disease (CKD) face an excessive burden of bone disease and fracture risk compared with the general population due to metabolic derangements related to renal disease as well as traditional fracture risk factors, osteoporosis and advancing age. Fragility fracture incidence increases with progressive renal impairment and age, and fractures in this group are associated with exaggerated morbidity and mortality. Despite this, the diagnosis and management of osteoporosis in CKD is not well understood and patients are frequently undertreated. This review summarises the current understanding of and recommendations for the diagnosis and management of osteoporosis in CKD and provides a pragmatic approach to fracture risk assessment and reduction in this population.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf228","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:25:29Z","timestamp":1752672329000},"source":"Crossref","is-referenced-by-count":15,"title":["Management of osteoporosis in chronic kidney disease"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0856-7016","authenticated-orcid":false,"given":"Nicole","family":"Henry","sequence":"first","affiliation":[{"name":"The Centre for Nephrology, The Royal Free Hospital and University College London Medical School , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hildebrand","sequence":"additional","affiliation":[{"name":"The Centre for Nephrology, The Royal Free Hospital and University College London Medical School , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Cunningham","sequence":"additional","affiliation":[{"name":"The Centre for Nephrology, The Royal Free Hospital and University College London Medical School , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2025101513175917500_bib1","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1001\/jama.288.23.3014","article-title":"Risk of hip fracture among dialysis and renal transplant recipients","volume":"288","author":"Ball","year":"2002","journal-title":"JAMA"},{"key":"2025101513175917500_bib2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0272-6386(04)00958-8","article-title":"Increased risk of mortality associated with hip fracture in the dialysis population","volume":"44","author":"Mittalhenkle","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2025101513175917500_bib3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jbmr\/zjae021","article-title":"Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study","volume":"39","author":"Hsu","year":"2024","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2025101513175917500_bib5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s12603-023-1971-4","article-title":"Sex specific global burden of osteoporosis in 204 countries and Territories, from 1990 to 2030: an age-period-cohort modeling study","volume":"27","author":"Zhu","year":"2023","journal-title":"J Nutr Health Aging"},{"key":"2025101513175917500_bib6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int"},{"key":"2025101513175917500_bib7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","article-title":"Chronic kidney disease\u2013mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int"},{"key":"2025101513175917500_bib8","article-title":"Chronic kidney disease-mineral bone disorder (CKD-MBD)","volume-title":"StatPearls","author":"Shah","year":"2024"},{"key":"2025101513175917500_bib9","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"2025101513175917500_bib10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.semnephrol.2014.09.008","article-title":"Adynamic bone disease: from bone to vessels in chronic kidney disease","volume":"34","author":"Bover","year":"2014","journal-title":"Semin Nephrol"},{"key":"2025101513175917500_bib11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","journal-title":"JAMA"},{"key":"2025101513175917500_bib12","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","article-title":"The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group","volume":"25","author":"Siris","year":"2014","journal-title":"Osteoporos Int"},{"key":"2025101513175917500_bib13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/j.ackd.2004.07.009","article-title":"Outcomes associated with hypogonadism in women with chronic kidney disease","volume":"11","author":"Weisinger","year":"2004","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025101513175917500_bib15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3389\/fped.2018.00161","article-title":"Malnutrition in chronic kidney disease","volume":"6","author":"Iorember","year":"2018","journal-title":"Front Pediatr"},{"key":"2025101513175917500_bib16","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"2025101513175917500_bib17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11914-005-0021-y","article-title":"Treatment of osteoporosis in chronic kidney disease and end-stage renal disease","volume":"3","author":"Miller","year":"2005","journal-title":"Curr Osteoporos Rep"},{"key":"2025101513175917500_bib18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/bonekey.2014.37","article-title":"Chronic kidney disease and osteoporosis: evaluation and management","volume":"3","author":"Miller","year":"2014","journal-title":"Bonekey Rep"},{"key":"2025101513175917500_bib19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11914-017-0364-1","article-title":"Renal osteodystrophy or kidney induced osteoporosis?","volume":"15","author":"Moe","year":"2017","journal-title":"Curr Osteoporos Rep"},{"key":"2025101513175917500_bib20","doi-asserted-by":"publisher","first-page":"E82","DOI":"10.5888\/pcd15.170518","article-title":"Falls and fall-related injuries among US adults aged 65 or older with chronic kidney disease","volume":"15","author":"Kistler","year":"2018","journal-title":"Prev Chronic Dis"},{"key":"2025101513175917500_bib21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013Mineral and bone disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"key":"2025101513175917500_bib22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","volume":"47","author":"Danese","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2025101513175917500_bib23","first-page":"650","article-title":"Adynamic bone disease","volume":"43","author":"Gueiros","year":"2021","journal-title":"J Bras Nefrol"},{"key":"2025101513175917500_bib24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1523-1755.2001.00794.x","article-title":"Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms","volume":"60","author":"Magnusson","year":"2001","journal-title":"Kidney Int"},{"key":"2025101513175917500_bib25","first-page":"237","article-title":"Harmonised Australian reference intervals for serum PINP and CTX in adults","volume":"35","author":"Vasikaran","year":"2014","journal-title":"Clin Biochem Rev"},{"key":"2025101513175917500_bib26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1359\/jbmr.1999.14.5.792","article-title":"Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices","volume":"14","author":"Woitge","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","article-title":"Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis","volume":"67","author":"Sprague","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2025101513175917500_bib28","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/ndt\/gfu055","article-title":"A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan","volume":"29","author":"Maruyama","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025101513175917500_bib29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00223-008-9127-4","article-title":"Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients","volume":"82","author":"Shidara","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"2025101513175917500_bib30","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2215\/CJN.12871211","article-title":"Bone mineral density and fracture risk in older individuals with CKD","volume":"7","author":"Yenchek","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025101513175917500_bib31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/jcm13041010","article-title":"Evaluating osteoporosis in chronic kidney disease: both bone quantity and quality matter","volume":"13","author":"Lloret","year":"2024","journal-title":"J Clin Med"},{"key":"2025101513175917500_bib32","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.bonr.2022.101169","article-title":"Bone mass measurement by DXA should be interpreted with caution in the CKD population with vascular calcification","volume":"16","author":"Campagnaro","year":"2022","journal-title":"Bone Rep"},{"key":"2025101513175917500_bib33","doi-asserted-by":"publisher","first-page":"116482","DOI":"10.1016\/j.bone.2022.116482","article-title":"Vascular calcification of the abdominal aorta has minimal impact on lumbar spine bone density in patients with chronic kidney disease","volume":"162","author":"J\u00f8rgensen","year":"2022","journal-title":"Bone"},{"key":"2025101513175917500_bib34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/jbmr.2734","article-title":"A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX","volume":"31","author":"McCloskey","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib35","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.00720116","article-title":"Trabecular bone score and incident fragility fracture risk in adults with reduced kidney function","volume":"11","author":"Naylor","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025101513175917500_bib36","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00198-018-4468-y","article-title":"The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease","volume":"29","author":"Aleksova","year":"2018","journal-title":"Osteoporos Int"},{"key":"2025101513175917500_bib37","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00198-020-05458-1","article-title":"Trabecular bone score in patients with chronic kidney disease","volume":"31","author":"Rampersad","year":"2020","journal-title":"Osteoporos Int"},{"key":"2025101513175917500_bib38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00223-013-9722-x","article-title":"High prevalence of vertebral fractures assessed by quantitative morphometry in hemodialysis patients, strongly associated with vascular calcifications","volume":"93","author":"Fusaro","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"2025101513175917500_bib39","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/diagnostics11050772","article-title":"The use of imaging techniques in chronic kidney disease-mineral and bone disorders (CKD-MBD)\u2014a systematic review","volume":"11","author":"Pimentel","year":"2021","journal-title":"Diagnostics"},{"key":"2025101513175917500_bib40","doi-asserted-by":"publisher","first-page":"e0171873","DOI":"10.1371\/journal.pone.0171873","article-title":"Cortical porosity not superior to conventional densitometry in identifying hemodialysis patients with fragility fracture","volume":"12","author":"Bielesz","year":"2017","journal-title":"PLoS One"},{"key":"2025101513175917500_bib41","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/jbmr.1916","article-title":"Rapid cortical bone loss in patients with chronic kidney disease","volume":"28","author":"Nickolas","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib42","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.2215\/CJN.09711010","article-title":"Bone microarchitecture in hemodialysis patients assessed by HR-pQCT","volume":"6","author":"Cejka","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025101513175917500_bib43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00198-017-4228-4","article-title":"Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors","volume":"29","author":"Malluche","year":"2018","journal-title":"Osteoporos Int"},{"key":"2025101513175917500_bib44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40618-023-02219-9","article-title":"An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis","volume":"47","author":"Schini","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"2025101513175917500_bib45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"key":"2025101513175917500_bib46","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2215\/CJN.06040614","article-title":"Comparison of fracture risk prediction among individuals with reduced and normal kidney function","volume":"10","author":"Naylor","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025101513175917500_bib47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.kint.2018.09.022","article-title":"The Fracture Risk Assessment Tool (FRAX\u00ae) predicts fracture risk in patients with chronic kidney disease","volume":"95","author":"Whitlock","year":"2019","journal-title":"Kidney Int"},{"key":"2025101513175917500_bib48","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-012-0665-8","article-title":"Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism","volume":"17","author":"Tsuruta","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"2025101513175917500_bib49","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.2215\/CJN.0000000000000254","article-title":"Changes in bone quality after treatment with etelcalcetide","volume":"18","author":"Khairallah","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025101513175917500_bib50","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2265.2011.04265.x","article-title":"Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism","volume":"76","author":"Lu","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025101513175917500_bib51","first-page":"581","article-title":"Efficacy and safety of anti-osteoporotic agents across CKD stages: a meta-analysis of randomized clinical trials","volume":"49","author":"Sabaghian","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"2025101513175917500_bib52","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/sdi.12388","article-title":"Pharmacology of bisphosphonates in patients with chronic kidney disease","volume":"28","author":"Ott","year":"2015","journal-title":"Semin Dial"},{"key":"2025101513175917500_bib53","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/jbmr.2361","article-title":"Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study","volume":"30","author":"Eastell","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib54","first-page":"123","article-title":"High bone-binding capacity of ibandronate in hemodialysis patients","volume":"25","author":"Bergner","year":"2005","journal-title":"Int J Clin Pharmacol Res"},{"key":"2025101513175917500_bib55","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"166","author":"Wilson","year":"2017","journal-title":"Ann Intern Med"},{"key":"2025101513175917500_bib58","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3676","article-title":"Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial","volume":"34","author":"Iseri","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib59","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000341864","article-title":"Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study","volume":"36","author":"Mitsopoulos","year":"2012","journal-title":"Am J Nephrol"},{"key":"2025101513175917500_bib60","first-page":"510","article-title":"Treatment of reduced bone density with ibandronate in dialysis patients","volume":"21","author":"Bergner","year":"2008","journal-title":"J Nephrol"},{"key":"2025101513175917500_bib61","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1440-1797.2005.00436.x","article-title":"Effects of short-term alendronate on bone mineral density in haemodialysis patients","volume":"10","author":"Wetmore","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"2025101513175917500_bib62","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ki.2008.193","article-title":"Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women","volume":"74","author":"Boonen","year":"2008","journal-title":"Kidney Int"},{"key":"2025101513175917500_bib63","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib64","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00198-012-2213-5","article-title":"Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study","volume":"24","author":"Kang","year":"2013","journal-title":"Osteoporos Int"},{"key":"2025101513175917500_bib65","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.1792","article-title":"Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis","volume":"28","author":"Wolfe","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib66","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","article-title":"Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial","volume":"56","author":"Toussaint","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2025101513175917500_bib67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00044011-200626040-00006","article-title":"Effect of etidronic acid on arterial calcification in dialysis patients","volume":"26","author":"Ariyoshi","year":"2006","journal-title":"Clin Drug Investig"},{"key":"2025101513175917500_bib68","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.kint.2021.04.043","article-title":"Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment","volume":"100","author":"Haarhaus","year":"2021","journal-title":"Kidney Int"},{"key":"2025101513175917500_bib69","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","article-title":"Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease","volume":"106","author":"Broadwell","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2025101513175917500_bib70","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib71","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/ajt.13692","article-title":"Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial","volume":"16","author":"Bonani","year":"2016","journal-title":"Am J Transplant"},{"key":"2025101513175917500_bib72","doi-asserted-by":"publisher","first-page":"167","DOI":"10.7326\/ANNALS-24-03237","article-title":"Cardiovascular safety and fracture prevention effectiveness of denosumab versus oral bisphosphonates in patients receiving dialysis: a target trial emulation","volume":"178","author":"Masuda","year":"2025","journal-title":"Ann Intern Med"},{"key":"2025101513175917500_bib73","doi-asserted-by":"publisher","first-page":"822178","DOI":"10.3389\/fphar.2022.822178","article-title":"Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025101513175917500_bib74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7326\/M24-0013","article-title":"The effect of denosumab on risk for emergently treated hypocalcemia by stage of chronic kidney disease\u202f: a target trial emulation","volume":"178","author":"Bird","year":"2025","journal-title":"Ann Intern Med"},{"key":"2025101513175917500_bib75","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"key":"2025101513175917500_bib76","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","article-title":"Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies","volume":"29","author":"Thongprayoon","year":"2018","journal-title":"Osteoporos Int"},{"key":"2025101513175917500_bib77","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jbmr.2043","article-title":"RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk","volume":"29","author":"Samelson","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib78","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib79","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/1744-9987.12867","article-title":"Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study","volume":"24","author":"Yamamoto","year":"2020","journal-title":"Ther Apher Dial"},{"key":"2025101513175917500_bib80","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","article-title":"Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study","volume":"27","author":"Sumida","year":"2016","journal-title":"Osteoporos Int"},{"key":"2025101513175917500_bib81","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000316708","article-title":"Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study","volume":"33","author":"Cejka","year":"2010","journal-title":"Kidney Blood Press Res"},{"key":"2025101513175917500_bib82","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/CIA.S120175","article-title":"Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study","volume":"11","author":"Nishikawa","year":"2016","journal-title":"Clin Interv Aging"},{"key":"2025101513175917500_bib83","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial","volume":"35","author":"Bilezikian","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2025101513175917500_bib84","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2215\/CJN.07670712","article-title":"The relation between renal function and serum sclerostin in adult patients with CKD","volume":"8","author":"Pelletier","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025101513175917500_bib85","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2215\/CJN.06550810","article-title":"Sclerostin and Dickkopf-1 in renal osteodystrophy","volume":"6","author":"Cejka","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025101513175917500_bib86","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ndt\/gfy129","article-title":"Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!","volume":"34","author":"Brandenburg","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2025101513175917500_bib87","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"2025101513175917500_bib88","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","article-title":"Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study","volume":"39","author":"Sato","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"2025101513175917500_bib89","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease","volume":"37","author":"Miller","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2025101513175917500_bib90","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","article-title":"One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study","volume":"112","author":"Saito","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"2025101513175917500_bib91","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1093\/ndt\/gfr620","article-title":"Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease","volume":"27","author":"West","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2025101513175917500_bib92","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00198-018-4650-2","article-title":"Diagnosis and management of bone fragility in diabetes: an emerging challenge","volume":"29","author":"Ferrari","year":"2018","journal-title":"Osteoporos Int"},{"key":"2025101513175917500_bib92a","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/genes13020279","article-title":"Functional Validation of Osteoporosis Genetic Findings Using Small Fish Models","volume":"13","author":"Kague","year":"2022","journal-title":"Genes"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf228\/63775579\/sfaf228.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/10\/sfaf228\/63775579\/sfaf228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/10\/sfaf228\/63775579\/sfaf228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:18:45Z","timestamp":1760548725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf228\/8203284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf228","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,7,16]]},"article-number":"sfaf228"}}